Bridgewater Associates LP acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 18,673 shares of the pharmaceutical company’s stock, valued at approximately $2,406,000.

A number of other large investors have also bought and sold shares of the stock. Guardian Life Insurance Co. of America boosted its stake in Vertex Pharmaceuticals by 0.6% during the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares in the last quarter. Elk Creek Partners LLC boosted its stake in Vertex Pharmaceuticals by 0.3% during the first quarter. Elk Creek Partners LLC now owns 3,120 shares of the pharmaceutical company’s stock worth $341,000 after acquiring an additional 10 shares in the last quarter. Sowell Financial Services LLC boosted its stake in Vertex Pharmaceuticals by 0.8% during the first quarter. Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company’s stock worth $325,000 after acquiring an additional 23 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Vertex Pharmaceuticals by 0.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock worth $2,385,000 after acquiring an additional 75 shares in the last quarter. Finally, Buckingham Asset Management LLC boosted its stake in Vertex Pharmaceuticals by 3.6% during the second quarter. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company’s stock worth $292,000 after acquiring an additional 79 shares in the last quarter. 92.88% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have issued reports on VRTX shares. Cowen and Company reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Jefferies Group LLC started coverage on shares of Vertex Pharmaceuticals in a report on Monday, July 10th. They issued a “buy” rating and a $155.00 target price for the company. Credit Suisse Group lifted their target price on shares of Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, July 19th. BidaskClub cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 28th. Finally, Maxim Group set a $195.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Six equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $163.35.

TRADEMARK VIOLATION NOTICE: “Bridgewater Associates LP Takes $2.41 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/15/bridgewater-associates-lp-takes-2-41-million-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

In other news, EVP David Altshuler sold 1,796 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the completion of the transaction, the executive vice president now directly owns 107,807 shares of the company’s stock, valued at $17,249,120. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Amit Sachdev sold 28,625 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.93, for a total value of $4,606,621.25. Following the transaction, the executive vice president now directly owns 119,335 shares of the company’s stock, valued at $19,204,581.55. The disclosure for this sale can be found here. Insiders have sold 526,092 shares of company stock worth $84,101,702 over the last quarter. Insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Incorporated (VRTX) traded up 0.290% during midday trading on Friday, reaching $153.825. 541,064 shares of the company were exchanged. The stock has a market capitalization of $38.78 billion, a P/E ratio of 147.767 and a beta of 1.75. The firm’s 50 day moving average price is $154.66 and its 200-day moving average price is $126.67. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.86.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. The company had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The business’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.